Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2373-8057

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects ; volume:8 ; number:1 ; day:10 ; month:9 ; year:2022 ; pages:1-22 ; date:12.2022
npj Parkinson's Disease ; 8, Heft 1 (10.9.2022), 1-22, 12.2022

Creator: Ho, Philip Wing-Lok
Chang, Eunice Eun-Seo
Leung, Chi-Ting
Liu, Huifang
Malki, Yasine
Pang, Shirley Yin-Yu
Choi, Zoe Yuen-Kiu
Liang, Yingmin
Lai, Weng Seng
Ruan, Yuefei
Leung, Kenneth Mei-Yee
Yung, Susan
Mak, Judith Choi-Wo
Kung, Michelle Hiu-Wai
Ramsden, David B.
Ho, Shu-Leong

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41531-022-00386-9

URN: urn:nbn:de:101:1-2022112821082640318657

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ho, Philip Wing-Lok
Chang, Eunice Eun-Seo
Leung, Chi-Ting
Liu, Huifang
Malki, Yasine
Pang, Shirley Yin-Yu
Choi, Zoe Yuen-Kiu
Liang, Yingmin
Lai, Weng Seng
Ruan, Yuefei
Leung, Kenneth Mei-Yee
Yung, Susan
Mak, Judith Choi-Wo
Kung, Michelle Hiu-Wai
Ramsden, David B.
Ho, Shu-Leong
SpringerLink (Online service)

Other Objects (12)

α-Synuclein oligomers form by secondary nucleation

Stabilization of α-synuclein oligomers using formaldehyde

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Structural characteristics and membrane interactions of tandem α-synuclein oligomers

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution

α-Synuclein oligomers form by secondary nucleation

Stabilization of α-synuclein oligomers using formaldehyde

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Structural characteristics and membrane interactions of tandem α-synuclein oligomers

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution

α-Synuclein oligomers form by secondary nucleation

Stabilization of α-synuclein oligomers using formaldehyde

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Structural characteristics and membrane interactions of tandem α-synuclein oligomers

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

α-Synuclein oligomers form by secondary nucleation

Stabilization of α-synuclein oligomers using formaldehyde

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Structural characteristics and membrane interactions of tandem α-synuclein oligomers

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution

α-Synuclein oligomers form by secondary nucleation

Stabilization of α-synuclein oligomers using formaldehyde

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Structural characteristics and membrane interactions of tandem α-synuclein oligomers

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution

α-Synuclein oligomers form by secondary nucleation

Stabilization of α-synuclein oligomers using formaldehyde

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Optical Structural Analysis of Individual α‐Synuclein Oligomers

Structural characteristics and membrane interactions of tandem α-synuclein oligomers

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution

Related objects

Reset password